A portable tuberculosis detection device that costs under $400 and delivers results within 30 minutes using a test priced at approximately four dollars, or around Rs. 1,100, has received a major endorsement from the World Health Organization, potentially opening the door to faster and more accessible tuberculosis diagnosis in low-resource settings including rural and underserved communities across Pakistan and other high-burden countries.
The device, called MiniDock MTB, works by detecting tuberculosis bacterial DNA from either a tongue swab or a phlegm sample. A healthcare worker collects the sample, places it in a tube, and the device processes it to produce results in as little as 12 to 25 minutes. Designed to function in small clinics, remote health posts, and other settings with limited infrastructure, it can run on a standard power bank or wall electricity and requires only minimal training to operate. The World Health Organization endorsed the test in March 2026, marking the first time the organisation has recommended a molecular tuberculosis test cleared for use in community settings without requiring full laboratory infrastructure, a significant threshold given how much of the global tuberculosis burden falls in areas where laboratory access remains limited or nonexistent.
The development addresses one of the most persistent challenges in tuberculosis control globally. Traditional smear microscopy, the most commonly used testing method in low-income settings, depends on phlegm samples that many patients including children, elderly individuals, and people living with Human Immunodeficiency Virus often struggle to produce. That method also misses a significant share of cases. In a multi-country clinical study involving 1,380 participants aged 12 and above, MiniDock MTB detected tuberculosis in 86 percent of tuberculosis-positive phlegm samples and 80 percent of tuberculosis-positive tongue swabs, with researchers confirming that its performance met the accuracy benchmarks set by the World Health Organization. While the device performs more reliably with phlegm than with tongue swabs, the swab option remains clinically meaningful for patients who cannot provide a usable phlegm sample.
The device does carry limitations that researchers acknowledge. It cannot yet detect drug-resistant strains of tuberculosis, and its sensitivity is reduced when bacterial concentrations are very low, which can occur in the early stages of infection. Researchers are also exploring next-generation tuberculosis diagnostic approaches based on blood markers, proteins, and metabolites, though those are still at earlier stages of development. For now, MiniDock MTB represents a practical and immediately deployable tool for expanding tuberculosis testing coverage in communities where the disease continues to go undetected and untreated at significant scale.
Follow the SPIN IDG WhatsApp Channel for updates across the Smart Pakistan Insights Network covering all of Pakistan’s technology ecosystem.
